Abstract

Orlistat (OR) an inhibitor of pancreatic lipase has been suggested to act on body weight, but its consequence on the metabolic derangements of obesity are controversial. We investigate the effects of OR in 90 obese patients, 76 females and 14 males, 28 white and 62 non white, age 45.6 ± 2.6 years). OR was given during 3 months, 120mg tid, accompanied by a low fat caloric diet. Results before and after treatment were: weight 99.9 ± 2.0 vs 95.7 ± 1.9 kg; BMI 38.9 ± 0.7 vs 37.3 ± 0.7 kg/m 2 ; waist circumference 113.5 ±1.6 vs 108.3 ± 1.5 cm; waist to hip ratio (WHR) 0.92 ± 0.01 vs 0.91 ± 0.01; total chol 226.8 ± 5.2 vs 208.6 ± 5.0 mg/dl; LDL chol 151.6 ± 4.9 vs 140.1 ± 4.4mg/dl; triglycerides 137.4 ± 6.8 Vs 121.6 ± 6.5mg/dl, systolic (135.0 ± 2.3 vs 127.4 ±1.6 mmHg), diastolic (85.4 ±1.9 vs 79.0 ± 1.6 mmHg), and mean blood pressure 101.9 ± 1.9 vs 95.2 ± 1.5 mmHg, in all the comparisons p < 0.0003. Neither HDL (45.9 ± 1.2 vs 44.5 ± 1.0 mg/dl) nor fibrinogen (367.4 ± 10.6 vs 361.2 mg/dl) were different before and after orlistat intervention. Changes of glucose levels were correlated to weight loss (r = 0.28, p < 0.008), as well as to changes on waist (r=0.28, p=0.02). The association remained significant with waist circumference after correction for body weight. The changes of triglycerides were correlated both to waist circumference (r = 0.29, p = 0.006) and WHR (r = 0.23, p < 0.03), even when corrected by regression analysis for changes in body weight. Levels of blood pressure were not associated to changes of weight, as well as to changes of anthropometric indexes. Conclusions: In our obese patients, orlistat actuates on metabolism of lipid and glucose independently of its role on body weight reduction.

This content is only available as a PDF.
You do not currently have access to this article.